PG-116800

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H27N3O7S
Molecular Weight	501.552
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC(CC#CCN3CCOCC3)C(O)=O

InChI

InChIKey=JAYVKNDQKXUNOJ-UHFFFAOYSA-N

InChI=1S/C24H27N3O7S/c1-33-20-9-5-18(6-10-20)23(28)25-19-7-11-21(12-8-19)35(31,32)26-22(24(29)30)4-2-3-13-27-14-16-34-17-15-27/h5-12,22,26H,4,13-17H2,1H3,(H,25,28)(H,29,30)

HIDE SMILES / InChI

Molecular Formula	C24H27N3O7S
Molecular Weight	501.552
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16814643 | https://www.ncbi.nlm.nih.gov/pubmed/17958901 | https://www.ncbi.nlm.nih.gov/pubmed/18096086 | https://adisinsight.springer.com/drugs/800020080

PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.

Originator

Approval Year

PubMed

Title	Date	PubMed
The quest for the Holy Grail: a disease-modifying osteoarthritis drug.	2007	18096086
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.	2007	17958901
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.	2006-07-04	16814643
Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.	2006-06	16428338
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.	2006-02-15	16413004
Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER.	2005-08	16087144

Sample Use Guides

In Vivo Use Guide

25 mg, 50 mg, 100 mg, or 200 mg taken twice daily for 12 months

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:13:45 GMT 2025` Edited by `admin` on `Mon Mar 31 21:13:45 GMT 2025`
Record UNII	F94T42GL80
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PG-116800

Code

English

PGE-7113313

Preferred Name

English

PGE7113313

Code

English

4-Hexynoic acid, 2-[[[4-[(4-methoxybenzoyl)amino]phenyl]sulfonyl]amino]-6-(4-morpholinyl)-

Systematic Name

English

PG-530742 free acid

Common Name

English

Code System Code Type Description

MESH

C512048